Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 3/2013

01-06-2013 | Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Do Statins Cause Diabetes?

Authors: Mark R. Goldstein, Luca Mascitelli

Published in: Current Diabetes Reports | Issue 3/2013

Login to get access

Abstract

A wealth of evidence has established that cholesterol-lowering statin drugs, widely used for the prevention of cardiovascular disease, do increase the risk of new-onset diabetes, possibly by impairing pancreatic beta cell function and decreasing peripheral insulin sensitivity. Groups at particular risk include the elderly, women, and Asians. The diabetogenic effect of statins appear directly related to statin dose and the degree of attained cholesterol lowering. Statins can cause hyperinsulinemia even in the absence of hyperglycemia and the potential mitogenic effects and implications of prolonged hyperinsulinemia are discussed. Suggestions are made as to how physicians might avert the hyperinsulinemic and diabetogenic effects of statin therapy in clinical practice, and modulate the detrimental effects of these drugs on exercise performance. Finally, long-term studies are needed to determine if the deleterious hyperinsulinemic and diabetogenic effects of statin therapy undermine the beneficial cardiovascular disease risk outcomes in various segments of the population.
Literature
1.
Gotto AM, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol. 2012;110(Suppl):3A–14A.PubMedCrossRef
2.
Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J. 1993;295:31–40.PubMed
3.
Ohrvall M, Lithell H, Johansson J, Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with noninsulin dependent diabetes mellitus and hyperlipoproteinemia. Metabolism. 1995;44:212–7.PubMedCrossRef
4.
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. For the JUPITER Study Group. N Engl J Med. 2008;359:2195–207.
5.
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–71.PubMedCrossRef
6.
Steinberg D. Earlier intervention in the management of hypercholesterolemia: what are we waiting for? J Am Coll Cardiol. 2010;56:627–9.PubMedCrossRef
7.
Pletcher MJ, Hulley SB. Statin therapy in young adults: ready for prime time? J Am Coll Cardiol. 2010;56:637–40.PubMedCrossRef
8.
Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Aging. 2010;39:674–80.CrossRef
9.
Simons LA, Simons J, Friedlander Y, McCallum J. Predictors of long-term mortality in the elderly: the Dubbo Study. Intern Med J. 2011;41:555–60.PubMedCrossRef
10.
Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Pressure Institute. Hypertension. 2008;52:30–6.
11.
Goldberg RB, Jacabson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc. 2008;83:470–8.PubMedCrossRef
12.
Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol. 2009;53:S28–34.PubMedCrossRef
13.
Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378:169–81.PubMedCrossRef
14.
Mascitelli L, Goldstein MR. Long-standing statin therapy and the risk of new-onset diabetes in the elderly: collateral damage caused by preventive medicine? Drugs Aging. 2010;29:9–13.CrossRef
15.
•• Campbell PT, Jacobs EJ, Newton CC, Gapstur SM, Patel AV. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35:1835–44. This very large 26-year observational study shows that diabetes is associated with an increased mortality from a variety of cancers in both men and women.PubMedCrossRef
16.
Barone BB, Yeh H-C, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64.
17.
Freeman DJ, Norrie J, Sattar N, Neely DG, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357–62.
18.
Keech A, Hague W, Colquhoun D, Beller E, Best J, Arulchelvam M, et al. For the LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26:2713–21.
19.
Shepherd J, Blauw MB, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. On behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–30.
20.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735–42.
21.
•• Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069–77. This post-hoc analysis of the JUPITER trial is notable for the women in the rosuvastatin group exhibiting a significant absolute increase in new-onset diabetes equal to the absolute decrease in the composite primary endpoint of cardiovascular disease events.
22.
Fugh-Berman A. Rosuvastatin in patients with elevated C-reactive protein. N Engl J Med. 2009;360:1038–9.PubMedCrossRef
23.
24.
Chan JCN, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K-H, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–40.
25.
Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Woman’s Health Initiative. Arch Intern Med. 2012;172:144–52.
26.
Zaharan NL, Williams D, Bennet K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2012. [Epub ahead of print].
27.
Rajpathak SN, Barzilai N, Kumbhani DJ, Alderman M, Crandall J, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32:1924–9.
28.
• Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy; a meta-analysis. JAMA. 2011;305:2556–64. This large meta-analysis shows that intensive compared with moderate-dose statin therapy is associated with a significantly greater risk of new-onset diabetes.
29.
Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009;204:483–90.
30.
Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycaemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55:1209–16.
31.
•• Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis H, et al. Comparison of the effects of simvastatin vs rosuvastatin vs simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract. 2011;65:1141–8. This study demonstrates that statin therapy can significantly increase fasting insulin levels without having an effect on fasting glucose or glycosylated hemoglobin levels.
32.
Koh KK, Ahn JY, Quon MJ, Kim SJ, Han SH, Koh Y, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31:776–82.
33.
Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia. 2008;51:701–13.CrossRef
34.
Defronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32:S157–63.PubMedCrossRef
35.
Xia F, Xie L, Mihic A, Gao X, Chen Y, Gaisano HY, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic β-cells. Endocrinology. 2008;149:5136–45.
36.
• Brown JE. The ageing pancreas. Br J Diabetes Vasc Dis. 2012;12:141–5. This interesting paper notes that the aging pancreas is associated with impaired beta cell function, implies that the elderly might be particularly sensitive to statin induced beta cell dysfunction.CrossRef
37.
•• Kwak H-B, Thalacker-Mercer A, Anderson EJ, Lin C-T, Kane DA, Lee N-S, et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med. 2012;52:198–207. This paper shows how simvastatin results in skeletal muscle mitochondrial dysfunction.
38.
Galtier F, Mura T, de Mauverger ER, Chevassus H, Farret A, Gagnol J-P, et al. Effect of high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers. Toxicol Appl Pharmacol. 2012;263:281–6.
39.
• Hoeks J, Schrauwen P. Muscle mitochondria and insulin resistance: a human perspective. Trends Endocrinol Metab. 2012;23:444–50. This interesting paper connects skeletal muscle mitochondrial dysfunction with insulin resistance.PubMedCrossRef
40.
Kusminski CM, Scherer PE. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol Metab. 2012;23:435–43.PubMedCrossRef
41.
• Supale S, Li N, Brun T, Maechler P. Mitochondrial dysfunction in pancreatic β cells. Trends Endocrinol Metab. 2012;23:477–87. This paper suggests pancreatic beta cell mitochondrial dysfunction leads to beta cell apoptosis and cell death.PubMedCrossRef
42.
Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 2001;507:357–61.PubMedCrossRef
43.
Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia. 2006;49:1881–92.
44.
Shepherd PR, Kahn BB. Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999;341:248–57.PubMedCrossRef
45.
Chidlow Jr JH, Sessa WC. Caveolae, caveolins, and cavins; complex control of cellular signaling and inflammation. Cardiovasc Res. 2010;86:219–25.PubMedCrossRef
46.
Breen MR, Camps M, Carvalho-Simoes F, Zorzano A, Pilch PF. Cholesterol depletion in adipocytes causes caveolae collapse concomitant with proteosomal degradation of cavin-2 in a switch-like fashion. PLoS One. 2012;7:e34516.
47.
González-Muñoz E, López-Iglesias C, Calvo M, Palacin M, Zorzano A, Camps M. Caveolin-1 loss of function accelerates glucose transporter 4 and insulin receptor degradation in 3T3-L1 adipocytes. Endocrinology. 2009;150:3493–502.
48.
Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409:729–33.
49.
• Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis. 2012. [Epub ahead of print]. This important study shows that muscular side effects from average doses of statins in real-life clinical situations are much more common than what has been seen in clinical trials.
50.
Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393–403.PubMedCrossRef
51.
Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210:94–102.
52.
Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172:1180–2.PubMed
53.
Scott D, Blizzard L, Fell J, Jones G. The epidemiology of sarcopenia in community living older adults: what role does lifestyle play? J Cachex Sarcopenia Muscle. 2011;2:125–34.CrossRef
54.
Khamseh ME, Malek M, Aghili R, Emami Z. Sarcopenia and diabetes: pathogenesis and consequences. Br J Diabetes Vasc Dis. 2011;11:230–4.CrossRef
55.
•• Zhou XH, Qiao Q, Zethelius B, Pyörälä K, Söderberg S, Pajak A, et al, for the DECODE Study Group. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010;53:1867–76. This large observational study shows that pre-diabetes and diabetes are risk factors for cancer mortality in men and women irrespective of body mass index.
56.
Noto H, Tsujimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: a meta-analysis of epidemiological evidence in Asians and non-Asians. J Diabetes Invest. 2012;3:24–33.CrossRef
57.
Tsugane S, Inoue M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 2010;101:1073–9.PubMedCrossRef
58.
Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia. 2010;53:2086–8.PubMedCrossRef
59.
Cowie CC, Williams DE, Rust KF, Gregg EW, Ford ES, Bainbridge KE, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005–2006. Diabetes Care. 2009;32:287–94.
60.
Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118–28.CrossRef
61.
DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409–18.PubMedCrossRef
62.
63.
• Pollak M. The insulin and insulin-like growth factor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159–69. This is a great review on the mechanisms of hyperinsulinemia and insulin growth factor signaling in oncogenesis.PubMed
64.
Giovannucci E, Habel LA, Harlan DM, Pollak M, Archer MC, Regensteiner JG, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–85.
65.
Wanders D, Plaisance EP, Judd RL. Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J Diabetes. 2010;1:116–28.PubMedCrossRef
66.
Jardé T, Perrier S, Vasson M-P, Caldefie-Chézet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer. 2011;47:33–43.PubMedCrossRef
67.
Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94:1221–5.PubMedCrossRef
68.
Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol. 2011;29:32–9.
69.
Goldstein MR, Mascitelli L. Statin-induced diabetes: perhaps, it’s the tip of the iceberg. Q J Med. 2011;104:174–8.CrossRef
70.
71.
• Sniderman A, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering. J Clin Lipidol. 2012;6:303–9. This paper challenges the dogma that achieving ultra-low cholesterol levels with maximal doses of statins yields significantly better clinical results.
72.
Ferenczi EA, Asaria P, Hughes AD, Chaturvedi N, Francis DP. Can a statin neutralize the cardiovascular risk of unhealthy dietary choices? Am J Cardiol. 2010;106:587–92.PubMedCrossRef
73.
Mizuno K, Tajima Y, Ohashi Y, Nakamura H. Is the risk of new-onset diabetes by statins associated with diet adherence? Int J Cardiol. 2012. [Epub ahead of print].
74.
Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, for the Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379:2243–51.
75.
Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Rönnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA. 2002;287:598–605.
76.
77.
Qi Q, Chu AY, Kang JH, Jensen MK, Curhan GC, Pasquale LR, et al. Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med. 2012;367:1387–96.
78.
Tappy L, Lê K-A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90:23–46.PubMedCrossRef
79.
Port AM, Ruth MR, Istfan NW. Fructose comsumption and cancer: is there a connection? Curr Opin Endocrinol Diabetes Obes. 2012;19:367–74.PubMed
80.
Pomeranz JL, Brownell KB. Portion sizes and beyond—Government’s legal authority to regulate food industry practices. N Engl J Med. 2012;367:1383–5.PubMedCrossRef
81.
82.
Lira VA, Benton CR, Yan Z, Bonen A. PGC-1α regulation by exercise training and its influences on muscle function and insulin sensitivity. Am J Physiol Endocrinol Metab. 2010;299:E145–61.PubMed
83.
• Grontved A, Rimm EB, Willett WC, Anderson LB, Hu FB. A prospective study of weight training and risk of type 2 diabetes mellitus in men. Arch Intern Med. 2012;172:1306–12. This paper suggests that combined resistance and endurance exercise provide the best results in decreasing the risk of diabetes.PubMed
84.
Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40:188–94.PubMed
85.
Deichmann R, Lavie C, Andrews S. Coenzyme Q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010;10:16–21.PubMed
86.
Binkley N, Ramamurthy R, Krueger D. Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin N Am. 2010;39:287–301.CrossRef
87.
Borges MC, Martini LA, Rogero MM. Current perspectives on vitamin D, immune system, and chronic diseases. Nutrition. 2011;27:399–404.PubMedCrossRef
88.
Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol. 2010;2010:351385.PubMed
89.
Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25(OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res. 2009;153:11–6.
90.
Booth FW, Hargreaves M. Understanding multi-organ pathology from insufficient exercise. J Appl Physiol. 2011;111:1199–200.PubMedCrossRef
91.
Thyfault JP, Krogh-Madsen R. Metabolic disruptions induced by reduced ambulatory activity in free-living humans. J Appl Physiol. 2011;111:1218–24.PubMedCrossRef
Metadata
Title
Do Statins Cause Diabetes?
Authors
Mark R. Goldstein
Luca Mascitelli
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 3/2013
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-013-0368-x

Other articles of this Issue 3/2013

Current Diabetes Reports 3/2013 Go to the issue

Pharmacologic Treatment of Type 2 Diabetes and Obesity (A Vella, Section Editor)

The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus

Diabetes and Other Diseases—Emerging Associations (D Aron, Section Editor)

Diabetes and Infections-Hepatitis C: Is There Type 2 Diabetes Excess in Hepatitis C Infection?

Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Is the Risk and Nature of CVD the Same in Type 1 and Type 2 Diabetes?

Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Exercise and Diabetes-Related Cardiovascular Disease: Systematic Review of Published Evidence from Observational Studies and Clinical Trials

Diabetes and Other Diseases—Emerging Associations (D Aron, Section Editor)

Diabetes Mellitus and Osteoporosis

Pharmacologic Treatment of Type 2 Diabetes and Obesity (A Vella, Section Editor)

The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits